title: Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
abstract: OBJECTIVE
  The clinical use of sodium ferric gluconate complex in iron-deficient pediatric patients receiving hemodialysis was recently approved. This study was designed to describe the pharmacokinetic parameters of the medication.
  
  
  METHODS
  Iron-deficient pediatric (< or = 15 yr) hemodialysis patients were randomly assigned to two doses (1.5 and 3.0 mg/kg) of sodium ferric gluconate complex. Blood samples taken during a 1-h infusion and at multiple intervals during 48 h were analyzed for total iron, transferrin-bound iron, and sodium ferric gluconate complex-bound iron.
  
  
  RESULTS
  Forty-nine patients (mean age 12.3 +/- 2.5 yr) participated in the study. Mean serum iron concentrations rapidly increased in a dosage-dependent manner. A rapid rise in total serum iron was followed by a slower, less prominent rise in transferrin-bound iron. This was qualitatively confirmed by visualization of the transferrin bands from polyacrylamide gel electrophoresis. Single-dose pharmacokinetics of sodium ferric gluconate complex-bound iron was described using noncompartmental analytical methods. Mean values for the 1.5 mg/Kg dose were as follows: t(1/2) 2.0 +/- 0.7 h, Cmax 1287 mcg/dl, Tmax 1.1 +/- 0.23 h, Cl 0.69 +/- 0.50 L/h, Vd 1.6 +/- 0.6 L, AUC(0-infinity). 9499 +/- 4089 mcg x hr/dl.
  
  
  CONCLUSIONS
  The infusion of sodium ferric gluconate complex to pediatric patients who receive hemodialysis appears to result in a delayed transfer of iron to transferrin, likely after an initial movement through the reticuloendothelial system. Differences noted between the pediatric and adult pharmacokinetic data may result from the unique aspects of the study populations and the respective study designs.
authors.affiliation: Department of Pediatrics, Section of Pediatric Nephrology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA. bwarady@cmh.edu
authors.forename: Bradley A
authors.initials: BA
authors.lastname: Warady
authors.forename: Paul A
authors.initials: PA
authors.lastname: Seligman
authors.forename: Naomi V
authors.initials: NV
authors.lastname: Dahl
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007501:Iron / Q000097:blood; D000090463:Iron Deficiencies; D008297:Male; D006435:Renal Dialysis; D014168:Transferrin / Q000378:metabolism
chemical_list: D005290:Ferric Compounds; D014168:Transferrin; D007501:Iron; C035552:ferric gluconate